DNX-2401: Phase II started

DNAtrix and Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.) began the open-label, U.S. Phase II CAPTIVE/KEYNOTE-192 trial to evaluate a single intratumoral injection of DNX-2401 followed 7-9 days later...